ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Hsp90 inhibitors can bind to Hsp90 and specifically inhibit its chaperone function, resulting in the degradation of HSP90-associated proteins, such as BCR-ABL (known as an Hsp90 client protein) in CML cells [13].